June 16, 2022
Thu 6:00 PM CEST
Thu 6:00 PM CEST
Web
The potential of Prosigna
What are the advantages of using a second-generation genomic test? What is the utility of intrinsic subtyping in the clinic? The past, present and future.
Veracyte
Veracyte develops actionable genomic tests to inform diagnosis and treatment decisions in thyroid cancer, lung cancer, breast cancer and idiopathic pulmonary fibrosis. Hear from your peers how they are integrating these tests into clinical practice.
Featured Live Events
September 27, 2022
Tue 6:00 PM CEST
Tue 6:00 PM CEST
Web
The history and evolution of PAM50 & Prosigna from the laboratory to the clinic: how accurate biological classification can be used to best treat your patients.
Live discussions and debates looking at the history and origins of PAM50 and Prosigna and the adoption process in a reference center in Germany: Heidelberg.